AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31012740 — intervention group
Group type: EXPERIMENTAL
Intervention: Math and science learning devices
Number of subjects: 250
Study 30653355 — intervention group
Group type: EXPERIMENTAL
Intervention: Board games training group
Number of subjects: 27
Study 30653355 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 27
Study 29166732 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 410
Study 25820754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 60 µg/kg/cycle
Number of subjects: 171
Study 25820754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 µg/kg/cycle
Number of subjects: 171
Study 25820754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 120 µg/kg/cycle
Number of subjects: 171
Study 25820754 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 5 µg/kg/day
Number of subjects: 171
Study 23448344 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel reloading (20 mg)
Number of subjects: 76
Study 23448344 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel reloading (300 mg)
Number of subjects: 76
Study 20509027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon α‐2b (peginterferon α‐2b) 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance)
Number of subjects: 32
Study 20509027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pegylated interferon α‐2b (peginterferon α‐2b)
Number of subjects: 32
Study 20108776 — intervention group
Group type: EXPERIMENTAL
Intervention: Kurarinol (600 mg glucose injection IV once a day for 1 month, followed by Kurarinol capsule orally three times a day for 2 months)
Number of subjects: 74
Study 20108776 — intervention group
Group type: COMPARATOR
Intervention: Silybin Meglumine Tablets (used in control group, same method and dosage as treatment group)
Number of subjects: 74
Study 17161432 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS) in the shock skills station
Number of subjects: 44
Study 17161432 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method (Control group)
Number of subjects: 44
Study 17161432 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulator (HPS)
Number of subjects: 44
Study 15197149 — intervention group
Group type: EXPERIMENTAL
Intervention: Current NSAID use
Number of subjects: 4975
Study 15197149 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 4975
Study 15197149 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and concurrent NSAIDs use
Number of subjects: 4975
Study 15197149 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and aspirin taken concomitantly
Number of subjects: 4975
Study 11496599 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocath (Ruschcare)
Number of subjects: 27
Study 11496599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofric (Astratech)
Number of subjects: 27
Study 11496599 — intervention group
Group type: EXPERIMENTAL
Intervention: Easycath (Coloplast)
Number of subjects: 27
Study 9593111 — intervention group
Group type: EXPERIMENTAL
Intervention: APO‐A1 major locus
Number of subjects: 970
Study 9593111 — intervention group
Group type: EXPERIMENTAL
Intervention: APO‐A1 effect on HDL2‐C
Number of subjects: 970
Study 7530738 — intervention group
Group type: EXPERIMENTAL
Intervention: T3Ag
Number of subjects: 32
Study 7530738 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of CD8+ T cells from peripheral blood mononuclear cells
Number of subjects: 32
Study 7530738 — intervention group
Group type: EXPERIMENTAL
Intervention: T3Ag stimulation
Number of subjects: 32
Study 7530738 — intervention group
Group type: EXPERIMENTAL
Intervention: T3Ag-stimulated anti-C100-3 antibody production
Number of subjects: 32
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfited lettuce
Number of subjects: 8
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apricots
Number of subjects: 8
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: White grape juice
Number of subjects: 8
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated potatoes (mashed potatoes)
Number of subjects: 8
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mushrooms
Number of subjects: 8
Study 3379229 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfited shrimp
Number of subjects: 8
Study 29584462 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated gum (200 mg caffeine)
Number of subjects: 10
Study 29584462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg caffeine)
Number of subjects: 10
Study 28734830 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice email plus $100 incentive
Number of subjects: 2245
Study 28734830 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice email
Number of subjects: 2245
Study 28734830 — intervention group
Group type: COMPARATOR
Intervention: Control email with phone number for scheduling
Number of subjects: 2245
Study 26169181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50mg/day for 6 weeks
Number of subjects: 239
Study 26169181 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10mg/day for 6 weeks
Number of subjects: 239
Study 26169181 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mirabegron 50mg/day and solifenacin 10mg/day for 6 weeks
Number of subjects: 239
Study 26169181 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 239
Study 24212838 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost/timolol
Number of subjects: 33
Study 24212838 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost/timolol
Number of subjects: 33
Study 24212838 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost/timolol
Number of subjects: 33
Study 20934856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal-legume snack (laddoo) (500 mg of calcium carbonate)
Number of subjects: 24
Study 20934856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate alone (500 mg)
Number of subjects: 24
Study 20934856 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified cereal-legume snack
Number of subjects: 24
Study 20934856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified cereal-legume snack (laddoo)
Number of subjects: 24
Study 20934856 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate alone
Number of subjects: 24
Study 19828122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cistus extract (CYSTUS052)
Number of subjects: 160
Study 19828122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17121895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches before operation
Number of subjects: 17
Study 17121895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin treatment for 3 days before chemotherapy using DCb
Number of subjects: 17
Study 17121895 — intervention group
Group type: COMPARATOR
Intervention: No nitroglycerin treatment
Number of subjects: 17
Study 17121895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin treatment
Number of subjects: 17
Study 15578397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent rifampin and pyrazinamide (RZ) therapy, given twice weekly for 2 months
Number of subjects: 423
Study 11721754 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 3510
Study 11721754 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 3510
Study 9305416 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A receptor antagonist)
Number of subjects: 12
Study 9305416 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo infusion
Number of subjects: 12
Study 7894212 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis (once a week for 3 years)
Number of subjects: 32
Study 7894212 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 32
Study 2691129 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily
Number of subjects: 165
Study 2691129 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril with diuretic
Number of subjects: 165
Study 2691129 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril with beta-blocker
Number of subjects: 165
Study 2691129 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 165
Study 4150435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 64
Study 4150435 — intervention group
Group type: COMPARATOR
Intervention: Dummy tablets
Number of subjects: 64
Study 30851740 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI guided GDFT
Number of subjects: 76
Study 30851740 — intervention group
Group type: COMPARATOR
Intervention: PPV guided GDFT
Number of subjects: 76
Study 28460562 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight-wire method (CG)
Number of subjects: 22
Study 28460562 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon technique (DT)
Number of subjects: 22
Study 25651134 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural insoles
Number of subjects: 20
Study 25651134 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 20
Study 23264396 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand-name L-thyroxine (Synthroid)
Number of subjects: 31
Study 23264396 — intervention group
Group type: COMPARATOR
Intervention: Generic L-thyroxine (Sandoz)
Number of subjects: 31
Study 21522070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose caffeine (Stay Alert™ gum, 85 mg caffeine)
Number of subjects: 10
Study 21522070 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (no caffeine)
Number of subjects: 10
Study 18555485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training on two computerized visual attention training tasks (VT1 and VT2) for at least 40 hours
Number of subjects: 32
Study 18555485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training on two computerized visual attention training tasks (VT1 and VT2)
Number of subjects: 32
Study 16750456 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 28
Study 16750456 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 28
Study 16750456 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg and 40 mg
Number of subjects: 28
Study 16750456 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (both doses)
Number of subjects: 28
Study 15730653 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution for patients with middle and small burn area (Na(+) = 130 mmol/L)
Number of subjects: 150
Study 15730653 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution for patients with large burn area
Number of subjects: 150
Study 15730653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline resuscitation for patients with large burn area (Na(+) = 174 mmol/L)
Number of subjects: 150
Study 15730653 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 150
Study 10930892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) based triple therapy
Number of subjects: 17
Study 10930892 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) based triple therapy
Number of subjects: 17
Study 8965746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-thyroxine and 150 micrograms iodine
Number of subjects: 49
Study 8965746 — intervention group
Group type: COMPARATOR
Intervention: Mono-L-thyroxine treatment (control group B)
Number of subjects: 49
Study 1507027 — intervention group
Group type: COMPARATOR
Intervention: Active control product
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Test products slightly better than the active control
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Test products not quite as good as the active control
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-t test applied to means of subject GI gingivitis scores
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformations of subject GI mean gingivitis scores
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in group means
Number of subjects: 0
Study 1507027 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% confidence interval for 100*R
Number of subjects: 0
Study 6338253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (10-day courses)
Number of subjects: 0
Study 31440343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour session using a novel framework based on education literature, individual review of previously written feedback, and deliberate practice in writing comments.
Number of subjects: 157
Study 27808415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem)
Number of subjects: 45
Study 26703371 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% E6005
Number of subjects: 62
Study 26703371 — intervention group
Group type: COMPARATOR
Intervention: 0.05% E6005
Number of subjects: 62
Study 26703371 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 62
Study 24778046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg for 6 weeks, starting at week 6 of gemcitabine therapy)
Number of subjects: 30
Study 24778046 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg for 12 weeks, starting at week 1 of gemcitabine therapy)
Number of subjects: 30
Study 22309617 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Business program (intervention group)
Number of subjects: 750
Study 22309617 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 750
Study 19730769 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage (CD)
Number of subjects: 110
Study 19730769 — intervention group
Group type: COMPARATOR
Intervention: Gravity drainage (GD)
Number of subjects: 110
Study 17712126 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity program (30 minutes homework/healthy snack time and 80 minutes physical activity)
Number of subjects: 100
Study 17712126 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 15580809 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg EGCG
Number of subjects: 36
Study 15580809 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EGCG
Number of subjects: 36
Study 15580809 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg EGCG
Number of subjects: 36
Study 15580809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11425411 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab bolus and 24 h infusion
Number of subjects: 7800
Study 11425411 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab bolus and 48 h infusion
Number of subjects: 7800
Study 11425411 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7800
Study 9482293 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal capsular polysaccharide vaccine
Number of subjects: 691
Study 9482293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 691
Study 7990452 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric service (study group)
Number of subjects: 40
Study 2536896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (10, 20, 40, and 80 mg every eight hours for one day)
Number of subjects: 20
Study 2536896 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (oral dose)
Number of subjects: 20
Study 30006792 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT-PHE (interactive text conversations with Peer Health Educators, plus five‐times‐a‐day automated theory‐based messages, plus a weekly self‐monitoring text‐message assessment)
Number of subjects: 286
Study 30006792 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT-Auto (daily automated messages and weekly self‐monitoring assessment)
Number of subjects: 286
Study 30006792 — intervention group
Group type: EXPERIMENTAL
Intervention: AO (weekly self‐monitoring assessment only)
Number of subjects: 286
Study 28545364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic lighting system
Number of subjects: 89
Study 28545364 — intervention group
Group type: COMPARATOR
Intervention: Conventional lighting
Number of subjects: 89
Study 28545364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher daily light exposure
Number of subjects: 89
Study 28545364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower daily light exposure
Number of subjects: 89
Study 25921747 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (50 mg) daily for 24 weeks
Number of subjects: 44
Study 25921747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23381973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10-100 mg single doses and 10 mg or 25 mg every 12 hours multiple doses)
Number of subjects: 40
Study 23381973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21799145 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate flow rate of 800 ml/min
Number of subjects: 42
Study 21799145 — intervention group
Group type: COMPARATOR
Intervention: Dialysate flow rate of 600 ml/min
Number of subjects: 42
Study 19783805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined periodontal and triple therapy
Number of subjects: 0
Study 19783805 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy alone
Number of subjects: 0
Study 16426268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS in healthy volunteers
Number of subjects: 16
Study 16426268 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS in migraine patients
Number of subjects: 16
Study 12931769 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral sedation with diazepam and local anesthetic
Number of subjects: 13
Study 12931769 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic only
Number of subjects: 13
Study 10710578 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer based clinical decision support system plus cardiovascular risk chart
Number of subjects: 614
Study 10710578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk chart alone
Number of subjects: 614
Study 10710578 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 614
Study 9188928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg once daily
Number of subjects: 342
Study 9188928 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg once daily
Number of subjects: 342
Study 9188928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study 1416574 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 1-gram dose of ciprofloxacin (single-dose group; n = 40)
Number of subjects: 128
Study 1416574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-gram dose of ciprofloxacin at admission and 24 hours later (2-dose group; n = 43)
Number of subjects: 128
Study 1416574 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of ciprofloxacin every 12 hours for 5 days (10-dose group; n = 35)
Number of subjects: 128
Study 3889004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (Mefoxin)
Number of subjects: 152
Study 3889004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 3889004 — intervention group
Group type: COMPARATOR
Intervention: None (absence of antibiotic prophylaxis)
Number of subjects: 152
Study 30588994 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene care, toothbrushing education, and fluoride varnish application once per week for 8 weeks
Number of subjects: 40
Study 30588994 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish application once per week for 8 weeks (Control)
Number of subjects: 40
Study 27726951 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy
Number of subjects: 777
Study 27726951 — intervention group
Group type: COMPARATOR
Intervention: Traditional excisional surgery
Number of subjects: 777
Study 23988443 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray, 100 μg dose
Number of subjects: 21
Study 23988443 — intervention group
Group type: COMPARATOR
Intervention: Sham 'spray' (untreated control)
Number of subjects: 21
Study 24032184 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuijiening plaster
Number of subjects: 60
Study 24032184 — intervention group
Group type: COMPARATOR
Intervention: SASP
Number of subjects: 60
Study 24032184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Kuijiening plaster + SASP)
Number of subjects: 60
Study 24032184 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Kuijiening plaster, SASP, combined therapy)
Number of subjects: 60
Study 20216301 — intervention group
Group type: EXPERIMENTAL
Intervention: ART interruption (drug conservation)
Number of subjects: 134
Study 20216301 — intervention group
Group type: COMPARATOR
Intervention: ART continuation (virological suppression)
Number of subjects: 134
Study 20216301 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 134
Study 18785525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan cervical disc replacement
Number of subjects: 59
Study 18785525 — intervention group
Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 59
Study 16469021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable bulbourethral sling (Argus)
Number of subjects: 48
Study 14528481 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (expectant or medical treatment)
Number of subjects: 0
Study 14528481 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 0
Study 14528481 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding serum human chorionic gonadotropin change and low serum progesterone levels
Number of subjects: 0